The chemotherapy drug Erlotinib targets the intracellular domain of EGFRvIII and EGFR, and thus the intervention by Erlotinib would presumably block EGFR related pathways such as PI3K pathway and inhibit tumor aggressiveness48. The gene discussed is EGFR; the disease is neoplasm.